Cite

HARVARD Citation

    Bonifacio, M. et al. (2018). Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy. Leukemia research. pp. 75-79. [Online]. 
  
Back to record